Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Q1 2024 Earnings Presentation
61 slides from Bristol-myers Squibb's earnings presentation, Apr 25, 2024
Slide 1: Q1 2024 Results
Q1 2024 Results April 25, 2024
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forwa
Slide 3: Chris Boerner, PhD
Q1 2024 Results Chris Boerner, PhD Board Chair and Chief Executive Officer 3
Slide 4: Q1 2024 overview
Q1 2024 overview Solid Commercial Performance Topline growth: +5% or +6% Ex-FX* Advanced our Pipeline Multiple regulatory approvals & clinical development milestones Strengthened long-term growth profile by diversifying in Closed Four Significant Deals Oncology & expanding in Neuroscience Actions un
Slide 5: Q1 2024 Performance
Q1 2024 Performance Commercial Research & Development1 Business Development Growth Portfolio Revenues: Regulatory approvals: Closed key acquisitions & +8% or +11% Ex-FX* YoY • Breyanzi in 3L+ CLL/SLL in U.S. global licensing deal $ in billions • Abecma in 3L+ MM in U.S. & EU $11.3 $11.9 • Reblozyl 1
Slide 6: KarXT: Potential first-in-class M1/M4 agonist with multi-billion-dollar peak sales opportunities
KarXT: Potential first-in-class M1/M4 agonist with multi-billion-dollar peak sales opportunities Significant market opportunity Differentiated profile supported by long-term data2,3,4 • Large population: 1.6M1 adults treated • Compelling efficacy: >75% patients for schizophrenia in the U.S. achievin
Slide 7: Strengthening the Company for the Transition Period & long-term growth
Strengthening the Company for the Transition Period & long-term growth Realizing internal cost savings of ~$1.5B by the end of 2025* • Identifying key assets and programs with highest potential • Streamlining decision-making & reducing management layers • Focusing R&D on higher ROI programs • Invest
Slide 8: Continued confidence delivering underlying growth in 2024
Continued confidence delivering underlying growth in 2024 2024 Guidance Highlights*1 Total Revenues Low single-digit increase affirmed Reported Rates Total Revenues Low single-digit increase affirmed Ex-FX Revised Non-GAAP EPS $0.40 - $0.70 Includes (~$6.73) impact from Acquired IPR&D & dilution fro
Slide 9: David Elkins
Q1 2024 Results David Elkins Executive Vice President and Chief Financial Officer 9
Slide 10: Composition of revenue is rapidly transitioning to the Growth Portfolio
Composition of revenue is rapidly transitioning to the Growth Portfolio Growth Portfolio Legacy Portfolio $ in billions +5% YoY, +6% Ex-FX* $7.1 $6.9 $4.4 $4.8 Other Growth Brands1 Other Mature Brands Q1 2023 Q1 2024 +8% +11% +2% +3% Legacy Growth YoY Ex-FX* YoY Ex-FX* *See “Forward-Looking Statemen
Slide 11: Q1 2024 Oncology product summary
Q1 2024 Oncology product summary Global Net Sales Opdivo: • U.S. impacted by inventory work down & timing of $M YoY % Ex-FX* % customer orders vs PY; continued demand growth across indications (e.g., upper GI & 1L lung) $2,078 (6%) (2%) • Ex-U.S. demand growth & expanded access Opdualag: $583 +15% +
Slide 12: Q1 2024 Cardiovascular product summary
Q1 2024 Cardiovascular product summary Eliquis: Best-in-class & leading OAC within category Global Net Sales • U.S. growth driven by strong underlying demand • Ex-U.S. continues to be #1 OAC in key international markets % $M YoY % Ex-FX* % Camzyos: First-in-class myosin inhibitor $3,720 +9% +9% • St
Slide 13: Q1 2024 Hematology product summary
Q1 2024 Hematology product summary Global Net Sales 1 $M YoY % Ex-FX* % Reblozyl: • Strong U.S. launch in 1L MDS-associated anemia $1,669 (5%) (4%) • Growth across a broad RS agnostic patient population, gaining momentum in the RS negative population $865 +4% +4% • EU 1L approval with a broad label
Slide 14: Q1 2024 Immunology product summary
Q1 2024 Immunology product summary Global Net Sales Sotyktu: First-in-class TYK2 inhibitor • Achieved goal of ~10K commercial scripts in Q1 % $M YoY % Ex-FX* % • Additional momentum driven by continued volume $798 +4% +6% growth and access improvement • Continued focus on demand growth and access $1
Slide 15: Q1 2024 Financial Performance
Q1 2024 Financial Performance US US GAAP GAAP Non-GAAP Non-GAAP * $ in billions, except EPS Q1 2024 Q1 2023 Q1 2024 Q1 2023 Total Revenues, net 11.9 11.3 11.9 11.3 Gross Margin % 75.3% 77.4% 75.5% 77.8% Operating Expenses1 5.1 4.1 4.3 4.0 Acquired IPR&D 12.9 0.1 12.9 0.1 Amortization of Acquired Int
Slide 16: Strategic approach to Capital Allocation
Strategic approach to Capital Allocation Cash flow from Operations $B • Prioritize opportunities to further diversify portfolio & strengthen long-term outlook focused Business mainly on bolt-ons & licensing opportunities Development ‒ Completed acquisitions of Mirati Therapeutics, Karuna Therapeutic
Slide 17: Actions to enhance productivity
Actions to enhance productivity Realizing internal cost savings of ~$1.5B by the end of 2025* • Focus on opportunities with the Cost savings across the organization highest potential ROI to drive that include: long-term growth Strengthening the • Reduction of management layers Company to • Prioritiz
Slide 18: 2024 Non-GAAP EPS guidance adjusted for impact of recently closed transactions
2024 Non-GAAP EPS guidance adjusted for impact of recently closed transactions 2024 Non-GAAP EPS Guidance* February Diluted EPS (Prior) $7.10 - $7.40 Acquired IPR&D Impact ($6.30) Dilution Impact (RayzeBio) ($0.13) Dilution Impact (Karuna) ($0.30) Total Deals Impact ($6.73) Revised Diluted EPS1,2 $0
Slide 19: Revised 2024 Guidance
Revised 2024 Guidance Non-GAAP* Key Highlights February (Prior) April (Revised) • No change to Revenue or Gross Margin Total Revenues Low single-digit increase No Change • No change to Operating Expenses Reported Rates Total Revenues • Other Income/(Expense) updated for Low single-digit increase No
Slide 20: Q1 2024 Results Q&A
Q1 2024 Results Q&A Chris Boerner, PhD David Elkins Samit Hirawat, MD Adam Lenkowsky Board Chair, Executive VP, Executive VP, Executive VP, Chief Executive Officer Chief Financial Officer Chief Medical Officer, Chief Commercialization Officer Global Drug Development 20
Slide 21: Q1 2024 Opdivo Sales Mix
Q1 2024 Opdivo Sales Mix U.S. Sales Mix Ex-U.S. Sales Mix 3% 25% 26% 25% 27% 8% 23% 19% 22% 22% Note: percentages are approximate Q1 2024 Results Not for Product Promotional Use 21
Slide 22: Q1 2024 Eliquis NBRx/TRx Share
Q1 2024 Eliquis NBRx/TRx Share NBRx Share – US TRx Share – US 22% 20% 24% 22% 8% 7% 14% 12% 70% 73% 62% 66% Q1 2023 Q1 2024 Q1 2023 Q1 2024 Eliquis Warfarin Other NOACs Rx Source: IQVIA Q1 2024 Results Not for Product Promotional Use 22
Slide 23: BMS released our 2023 ESG report with strong progress
BMS released our 2023 ESG report with strong progress Advancing Patient Health Expanding the Boundaries Fostering a High-Performing & Reducing our Around the World of Science Inclusive Global Workforce Environment Impact 12M+ 26% 9 People reached through BMS’ Racially diverse clinical trial patient
Slide 24: Clinical Development Portfolio — Phase I and II
Clinical Development Portfolio — Phase I and II Data as of April 25th, 2024 Phase I Phase II Anti-CCR8^ Solid Tumors Anti-Fucosyl GM1^ RR Small Cell Lung Cancer 1L, 2L+ Metastatic Castration-Resistant Prostate Anti-IL-8^ Solid Tumors AR LDD Cancer Non-Small Cell Lung Cancer farletuzumab ecte
Slide 25: Clinical Development Portfolio — Phase III
Clinical Development Portfolio — Phase III Data as of April 25th, 2024 Phase III Registration US, EU, JP 1L Non-Small Cell Lung Cancer PD-L1≥50% ROS1 NSCLC (EU, JP) KRAZATI 2L Colorectal Cancer AUGTYRO Adjuvant Hepatocellular Carcinoma NTRK Pan-Tumor (US, EU) OPDIVO Peri-adjuvant Muscle-Invasive Uro
Slide 26: Broadening our registrational pipeline
Broadening ourour Strengthening registrational pipeline registrational pipeline Key Opportunities 5 Oncology 8 Hematology Planned 1L lung alnuctamab Iberdomide mezigdomide Ph3 study subcutaneous nivolumab RYZ101 (225Ac) golcadomide GPRC5D CAR T 3 Immunology 2 Cardiovascular 1 Neuroscience KarXT1 LPA
Slide 27: Q1 2024 key clinical trials update
Data as of April 25th, 2024 Q1 2024 key clinical trials update Oncology Hematology Immunology Cardiovascular Neuroscience • Augtyro • Abecma • Zeposia • Camzyos • KarXT • Opdivo • Breyanzi • Sotyktu • milvexian • Anti-MTBR-Tau • Opdualag • Reblozyl • cendakimab • MYK-224 • Krazati • BMS-986393 • LPA
Slide 28: Augtyro (ROS1/NTRK)
Oncology Hematology Immunology Cardiovascular Neuroscience Augtyro (ROS1/NTRK) Indication ROS1 NSCLC & NTRK+ Solid Tumors Phase/Study Phase I/II – TRIDENT-1 # of Patients N = 500 Phase I: • Dose escalation; food-effect, dose escalation with food; & Midazolam DDI Phase II: Expansion cohorts • ROS1 TK
Slide 29: Opdivo (anti-PD1)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdivo (anti-PD1) Indication Peri-Adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC Stage III Unresectable NSCLC Phase III – ANVIL Phase III – CheckMate -73L Phase/Study Phase III – CheckMate -77T Non-BMS Sponsored* # of Patients N = 452 N = 903 N
Slide 30: Opdivo (anti-PD1)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdivo (anti-PD1) Indication Peri-Adjuvant MIUC Adjuvant HCC Phase/Study Phase III – CA017-078 Phase III – CheckMate -9DX # of Patients N = 861 N = 545 • Opdivo 360 mg Q3W for four cycles + chemotherapy • Opdivo 480 mg Q4W • Chemotherapy • P
Slide 31: Opdivo (anti-PD1)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdivo (anti-PD1) Indication 1L HCC 1L+ MSI High CRC Phase/Study Phase III – CheckMate -9DW Phase III – CheckMate -8HW # of Patients N = 732 N = 831 • Opdivo 1 mg/kg + Yervoy 3 mg/kg Q3W up to four doses, • Opdivo 240 mg Q2W for six cycles,
Slide 32: Opdivo (anti-PD1)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdivo (anti-PD1) Indication 1L MIUC 2L RCC SC Phase/Study Phase III – CheckMate -901 Phase III – CheckMate -67T # of Patients N = 1,290 N = 454 • PD-L1+ & cis-ineligible: Opdivo 1 mg/kg + Yervoy 3 mg/kg Q3W • Opdivo 1200 mg Q4W + rHuPH20 Q4
Slide 33: Opdualag (anti-LAG3 + anti-PD1 FDC)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdualag (anti-LAG3 + anti-PD1 FDC) Indication Adjuvant Melanoma 1L Melanoma SC Phase/Study Phase III – RELATIVITY-098 Phase III – RELATIVITY-127 # of Patients N = 1050 N = 814 • Relatlimab + nivolumab FDC 160 mg/480 mg Q4W • Relatlimab + ni
Slide 34: Opdualag (anti-LAG3 + anti-PD1 FDC)
Oncology Hematology Immunology Cardiovascular Neuroscience Opdualag (anti-LAG3 + anti-PD1 FDC) Indication 1L Stage IV NSCLC 1L HCC Phase/Study Phase II – CA224-104 Phase I/II - RELATIVITY-106 # of Patients N = 420 N = 162 Part I: • Nivolumab + relatlimab + bevacizumab • Nivolumab + relatlimab Dose 1
Slide 35: Krazati (KRAS G12C inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience Krazati (KRASG12C inhibitor) Indication 1L NSCLC PD-L1≥ 50% 1L NSCLC PD-L1<50% Phase/Study Phase II/III – KRYSTAL-7 Phase II – KRYSTAL-17 # of Patients N = 806 N = 90 Phase II: • Cohort A: Adagrasib 400 mg BID for 2 cycles followed by adagra
Slide 36: Krazati (KRAS G12C inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience Krazati (KRASG12C inhibitor) Indication 2L CRC 3L+ CRC, 2-3L Pancreatic, Advanced Solid Tumors Phase/Study Phase III – KRYSTAL-10 Phase I/II – KRYSTAL-1 # of Patients N = 461 N = 822 • Adagrasib + cetuximab Phase I: • Chemotherapy • Dose exp
Slide 37: RYZ101 225Ac-DOTATE (SSTR2 inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience RYZ101 225Ac-DOTATE (SSTR2 inhibitor) Indication 2L+ GEP-NETs* Phase/Study Phase Ib/III – ACTION-1 # of Patients Phase Ib N=17; Phase III N = 288 Phase Ib dose escalation: • RYZ101 q8 weeks x 4 infusions Design Phase III: • RYZ101 10.2 MBq Q
Slide 38: BMS-986507 (EGFR x HER3 ADC)
Oncology Hematology Immunology Cardiovascular Neuroscience BMS-986507 (EGFR x HER3 ADC) Indication 1L NSCLC Phase I – LUNG-101 Phase/Study Non-BMS Sponsored* # of Patients N = 100 • BMS-986507 cohort A • BMS-986507 cohort B Design Primary: Safety & tolerability Secondary: PK, ORR Endpoints • Recruit
Slide 39: Abecma (anti-BCMA CAR T)
Oncology Hematology Immunology Cardiovascular Neuroscience Abecma (anti-BCMA CAR T) Indication NDMM with Suboptimal Response post-ASCT Phase/Study Phase III – KarMMa-9 # of Patients N = 618 • Abecma followed by lenalidomide maintenance • Lenalidomide maintenance therapy alone Design • Primary: PFS •
Slide 40: Breyanzi (anti-CD19 CAR T)
Oncology Hematology Immunology Cardiovascular Neuroscience Breyanzi (anti-CD19 CAR T) Indication R/R NHL R/R iNHL Phase/Study Phase I/II – TRANSCEND Phase II – TRANSCEND FL # of Patients N = 385 N = 213 • Breyanzi • Breyanzi Study included R/R DLBCL, MCL, FL 3B, & PMBCL iNHL includes 3L+ FL, 2L FL (
Slide 41: Reblozyl (Erythroid Maturation Agent)
Oncology Hematology Immunology Cardiovascular Neuroscience Reblozyl (Erythroid Maturation Agent) 1L TD Myelofibrosis (MF) 1L NTD Low-or Intermediate Risk Indication Associated Anemia Myelodysplastic Syndrome (MDS) Associated Anemia Phase/Study Phase III – INDEPENDENCE Phase III – ELEMENT-MDS # of Pa
Slide 42: Reblozyl (Erythroid Maturation Agent)
Oncology Hematology Immunology Cardiovascular Neuroscience Reblozyl (Erythroid Maturation Agent) TD & NTD Alpha-Thalassemia Indication (Ex-US study) Phase/Study Phase II – CA056-015 # of Patients N = 177 • Reblozyl 1.0 mg/kg SC Q3W • Placebo SC Q3W + Best Supportive Care Design Primary: • TD: ≥50% r
Slide 43: BMS-986393 (GPRC5D CAR T)
Oncology Hematology Immunology Cardiovascular Neuroscience BMS-986393 (GPRC5D CAR T) Indication 4L+ MM* Phase/Study Phase II – QUINTESSENTIAL # of Patients N = 150 • BMS-986393 Design • Primary: ORR in prior 4L+ Endpoints • Key secondary: CRR in prior 4L+, ORR and CRR in all prior 3L+, BOR of PR • R
Slide 44: alnuctamab (BCMA x CD3 T-Cell Engager)
Oncology Hematology Immunology Cardiovascular Neuroscience alnuctamab (BCMA x CD3 T-Cell Engager) Indication 2-4L MM 3L+ MM Phase/Study Phase III – ALUMMINATE Phase I/II – CA058-002 # of Patients N = 466 N = 156 • alnuctamab 3/6/30 mg SC • Part A1: alnuctamab SC + mezigdomide + dex • Investigator’s
Slide 45: iberdomide (CELMoD)
Oncology Hematology Immunology Cardiovascular Neuroscience iberdomide (CELMoD) Indication 2L+ MM Post-Transplant Maintenance NDMM Phase/Study Phase III – EXCALIBER Phase III – EXCALIBER-Maintenance # of Patients N = 864 N = 1216 • Iberdomide 1.0, 1.3, 1.6 mg + daratumumab 1800 mg + dex • Iberdomide
Slide 46: mezigdomide (CELMoD)
Oncology Hematology Immunology Cardiovascular Neuroscience mezigdomide (CELMoD) Indication 2L+ MM 2L+ MM Phase/Study Phase III – SUCCESSOR-1 Phase III – SUCCESSOR-2 # of Patients N = 810 N = 575 • Mezigdomide 0.3, 0.6, 1.0 mg + bortezomib 1.3 mg/m2a + dex • Mezigdomide 0.3, 0.6, 1.0 mg + carfilzomib
Slide 47: golcadomide (CELMoD)
Oncology Hematology Immunology Cardiovascular Neuroscience golcadomide (CELMoD) Indication High-Risk 1L LBCL Phase/Study Phase III – GOLSEEK-1 # of Patients N = 850 • Golcadomide 0.4 mg + R-CHOP • Placebo + R-CHOP Design • Primary: PFS • Key secondary: OS, EFS Endpoints • Trial initiating Status • P
Slide 48: Zeposia (S1P agonist)
Oncology Hematology Immunology Cardiovascular Neuroscience Zeposia (S1P agonist) Indication YELLOWSTONE Program: Crohn’s Disease (CD) – Moderate to Severe Phase III – RPC01-3201 Phase III – RPC01-3202 Phase III – RPC01-3203 Phase/Study (Induction I) (Induction II) (Maintenance) # of Patients N = 625
Slide 49: Sotyktu (TYK-2 inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience Sotyktu (TYK-2 inhibitor) Indication Psoriatic Arthritis (PsA) Phase/Study Phase III – POETYK-PsA-1 Phase III – POETYK-PsA-2 # of Patients N = 650 N = 700 52-week study of patients with active PsA in TNF-naïve patients 52-week study of patie
Slide 50: Sotyktu (TYK-2 inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience Sotyktu (TYK-2 inhibitor) Indication Systemic Lupus Erythematosus (SLE) Discoid Lupus Erythematosus (DLE) Sjogren’s (SjS) Phase/Study Phase III – POETYK SLE-1 Phase III – POETYK SLE-2 Phase II - IM011-132 Phase III – POETYK SjS-1 # of Patien
Slide 51: cendakimab (anti-IL-13)
Oncology Hematology Immunology Cardiovascular Neuroscience cendakimab (anti-IL-13) Eosinophilic Gastroenteritis (EGE) Indication Eosinophilic Esophagitis (EoE) (Japan study) Phase/Study Phase III – CC-93538-EE-001 Phase III – CC-93538-EG-001 # of Patients N = 430 N = 48 • Cendakimab 360 mg SC QW for
Slide 52: LPA1 Antagonist
Oncology Hematology Immunology Cardiovascular Neuroscience LPA1 Antagonist Indication Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis Phase/Study Phase III – ALOFT-IPF Phase III – ALOFT-PPF # of Patients N = 1185 N = 1092 • LPA1 Dose 60 mg BID • LPA1 Dose 60 mg BID • LPA1 Dose 120 mg BI
Slide 53: obexelimab (CD19 x FcγRIIB bifunctional mAb)
Oncology Hematology Immunology Cardiovascular Neuroscience obexelimab (CD19 x FcγRIIB bifunctional mAb) Indication IgG4-Related Disease Phase III – INDIGO Phase/Study Non-BMS Sponsored* # of Patients N = 200 • Obexelimab SC • Placebo SC Design • Primary: Time to first IgG4-RD flare that requires ini
Slide 54: Camzyos (myosin inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience Camzyos (myosin inhibitor) Indication Heart Failure with Preserved Ejection Fraction (HFpEF) Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Phase/Study Phase II – EMBARK Phase III – ODYSSEY-HCM # of Patients N = 35 N = 420 • Camzyos • Ca
Slide 55: milvexian (FXIa inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience milvexian (FXIa inhibitor) Indication Secondary Stroke Prevention Acute Coronary Syndrome Non-Valvular Atrial Fibrillation Phase III – LIBREXIA-STROKE Phase III – LIBREXIA-ACS Phase III – LIBREXIA-AF Phase/Study Non-BMS Sponsored* Non-BMS Sp
Slide 56: MYK-224 (myosin inhibitor)
Oncology Hematology Immunology Cardiovascular Neuroscience MYK-224 (myosin inhibitor) Indication Heart Failure with Preserved Ejection Fraction (HFpEF) Phase/Study Phase IIa – AURORA-HFpEF # of Patients N = 48 • MYK-224 • Placebo Design Primary: • TEAEs and SAEs • AEs leading to treatment discontinu
Slide 57: KarXT (M1/M4 muscarinic agonist & M1 antagonist)
Oncology Hematology Immunology Cardiovascular Neuroscience KarXT (M1/M4 muscarinic agonist & M1 antagonist) Indication Schizophrenia Phase/Study Phase III – EMERGENT-2 Phase III – EMERGENT-3 # of Patients N = 252 N = 256 • KarXT 50 mg/20 mg BID, 100 mg/20 mg BID, 125 mg/30 mg BID* • KarXT 50 mg/20 m
Slide 58: KarXT (M1/M4 muscarinic agonist & M1 antagonist)
Oncology Hematology Immunology Cardiovascular Neuroscience KarXT (M1/M4 muscarinic agonist & M1 antagonist) Indication Adjunctive Schizophrenia Phase/Study Phase III – ARISE # of Patients N = 400 • KarXT 50 mg/20 mg, 75mg/20 mg BID, 100mg/20 mg BID, 125mg/30 mg BID* • Placebo Design • Primary: Chang
Slide 59: KarXT (M1/M4 muscarinic agonist & M1 antagonist)
Oncology Hematology Immunology Cardiovascular Neuroscience KarXT (M1/M4 muscarinic agonist & M1 antagonist) Indication Psychosis in Alzheimer’s Disease Phase/Study Phase III – ADEPT-1 Phase III – ADEPT-2 # of Patients N = 380 N = 400 • KarXT 20 mg/2 mg TID, 30 mg/3 mg TID, 40 mg/4 mg • KarXT 20 mg/2
Slide 60: BMS-986446 (anti-MTBR-tau)
Oncology Hematology Immunology Cardiovascular Neuroscience BMS-986446 (anti-MTBR-tau) Indication Alzheimer's Disease Phase/Study Phase II – TargetTau-1 # of Patients N = 475 • BMS-986446 Dose A • BMS-986446 Dose B • Placebo Design Primary: • Mean change from baseline in CDR-SB score Endpoints Second
Slide 61: Abbreviations
Oncology Hematology Immunology Cardiovascular Neuroscience Abbreviations American Association for Cancer International Conference on Malignant Non-Obstructive Hypertrophic AACR cTnT Cardiac Troponin T ICML nHCM RFS Recurrence-free survival Research Lymphoma Cardiomyopathy Ac Actinium Dd Daratumumab–
Bristol-Myers Squibb Company — Q1 2024 Earnings Presentation on 6ix